PONTE VEDRA, Fla., April 11, 2024  /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, will present at Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET. The formal presentation will feature a ...